Radioimmunotherapy for B-cell non-Hodgkin lymphoma

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Radioimmunotherapy is an established and effective treatment in B-cell non-Hodgkin lymphoma (NHL). Currently, two radioimmunoconjugates (RICs) are approved for clinical use in the United States, ibritumomab tiuxetan and tositumomab. Both agents target the CD20 antigen on B-cell lymphoma cells. Although there are differences between these two agents, such as different murine monoclonal antibodies, radioisotopes, and dosimetry techniques,, they share similar toxicity and efficacy profiles. These anti-CD20 RICs are active in patients who are refractory to single-agent rituximab, documenting the added value of the conjugated radioisotope. This review focuses on the current use of these agents in the treatment of previously untreated indolent NHL and relapsed/refractory and transformed NHL.

Original languageEnglish (US)
Pages (from-to)225-231
Number of pages7
JournalClinical Advances in Hematology and Oncology
Issue number3
StatePublished - Mar 2006


  • CD20
  • Ibritumomab tiuxetan
  • NHL
  • Radioimmunotherapy
  • Tositumomab

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Radioimmunotherapy for B-cell non-Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this